GMAB - JNJ multiple myeloma therapy outperforms standard of care by 58%
2023-12-12 13:17:41 ET
More on Johnson & Johnson
- Johnson & Johnson Vs. Pfizer: Better Pharma Stock?
- Stocks To Watch: Big Week On Tap For McDonald's, Shopify, GameStop, And Johnson & Johnson
- Johnson & Johnson: Sleep Well At Night With The Only AAA-Rated Dividend Aristocrat
- Vanda stock jumps on $100M license deal for MS drug from J&J unit
- Goldman Sachs: Top 30 mutual fund underweight holdings, including Apple and Tesla
For further details see:
JNJ multiple myeloma therapy outperforms standard of care by 58%